Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer’s Disease

TOKYO, Apr 20, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer’s Disease with Lecanemab, an Anti-Abeta Protofibril Antibody, in the peer-reviewed journal Alzheimer’s Research and Therapy. The manuscript describes results […]

TOT BIOPHARM Announces A Number of Key Anti-Tumor Drugs Have Entered the Pivotal Clinical Stage in 2020

HONG KONG, Mar 24, 2021 – (ACN Newswire via SEAPRWire.com) – TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies, announced today its audited annual results for the year ended 31 December 2020. Milestones of 2020 Annual […]

APOLLOMICS, INC ANNOUNCES SUCCESSFUL ENROLLMENT OF FIRST PATIENT INTO PHASE 1 CLINICAL TRIAL OF APL-106 (UPROLESELAN INJECTION) IN CHINA

FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, CHINA, Mar 4, 2021 – (ACN Newswire via SEAPRWire.com) – Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully enrolled into a Phase 1 clinical trial of APL-106 (uproleselan injection) for […]

Cavite sees ‘infirmities’ in MacroAsia-CCCC’s Sangley submissions

Final decision this week on consortium’s bid for first phase of $10-B airport project By Arjay L. Balinbin, Senior Reporter THE Cavite government saw “infirmities” in the required documents submitted by the consortium of MacroAsia Corp. (MAC) and China Communications Construction Co. Ltd. (CCCC) for the Sangley Point International Airport project, the province’s top official […]

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China

HONG KONG, Jan 18, 2021 – (ACN Newswire) – SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the first healthy subject was successfully dosed in the Phase […]